Brittle bone breakthrough? new drug combo aims to cut fractures
NCT ID NCT03735537
First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study tested whether a two-year course of teriparatide (a bone-building drug) followed by a single infusion of zoledronic acid (a bone-strengthening drug) could reduce fractures in adults with osteogenesis imperfecta, also known as brittle bone disease. 350 participants were randomly assigned to receive either this drug combination or standard care. The main goal was to see if fewer people in the drug group experienced a broken bone.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
teriparatide (a bone-building drug) and zoledronic acid (a bone-strengthening drug)
What this could lead to
If it works, this could provide a new treatment option to reduce fractures in adults with brittle bone disease.
What could go wrong
This is a completed phase 4 trial, but results may not apply to all types of osteogenesis imperfecta. The treatment involves two drugs with potential side effects like bone pain or kidney issues.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for OSTEOGENESIS IMPERFECTA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Aberdeen Royal Infirmary
Aberdeen, AB25 2ZR, United Kingdom
-
Addenbrooke's Hospital
Cambridge, CB2 0QQ, United Kingdom
-
Bristol Royal Infirmary
Bristol, NS2 8HW, United Kingdom
-
Freeman Hospital
Newcastle upon Tyne, NE7 7DN, United Kingdom
-
Guy's and St Thomas' Hospital
London, SE1 9RT, United Kingdom
-
Haywood Community Hospital
Stoke-on-Trent, ST6 7AG, United Kingdom
-
James Cook University Hospital
Middlesbrough, PS4 3BW, United Kingdom
-
Leicester Royal Infirmary
Leicester, LE1 5WW, United Kingdom
-
Llandough University Hospital
Llandough, CF64 2XX, United Kingdom
-
Manchester Royal Infirmary
Manchester, M13 9WL, United Kingdom
-
Ninewells Hospital
Dundee, DD1 9SY, United Kingdom
-
Northern General Hospital
Sheffield, S5 7AU, United Kingdom
-
Nottingham City Hospital
Nottingham, NG5 1PD, United Kingdom
-
Nuffield Orthopaedic Centre
Oxford, OX3 7HE, United Kingdom
-
Queen Elizabeth Hospital
Birmingham, B15 2TH, United Kingdom
-
Queen Elizabeth University Hospital
Glasgow, G51 4TF, United Kingdom
-
Royal Liverpool Hospital and Aintree Hospital
Liverpool, L7 8XP, United Kingdom
-
Royal National Orthopaedic Hospital
Stanmore, HA7 4LP, United Kingdom
-
Royal Victoria Hospital
Belfast, BT12 6BA, United Kingdom
-
St Vincent's Hospital
Dublin, 4, Ireland
-
University Hospital Southampton
Southampton, S016 6YD, United Kingdom
-
Western General Hospital
Edinburgh, EH4 2XU, United Kingdom
-
Wishaw General Hospital
Wishaw, ML2 0DP, United Kingdom